Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

18.79
-0.4850-2.52%
Volume:370.32K
Turnover:7.02M
Market Cap:2.36B
PE:-10.46
High:19.25
Open:19.10
Low:18.75
Close:19.27
Loading ...

Apellis price target lowered to $44 from $47 at BofA

TIPRANKS
·
03 Mar

Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
01 Mar

Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

GuruFocus.com
·
01 Mar

Q4 2024 Apellis Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
01 Mar

Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts

TIPRANKS
·
01 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines

Reuters
·
28 Feb

Stock Track | Apellis Pharmaceuticals Plummets 5.31% Despite Better-Than-Expected Q4 Earnings

Stock Track
·
28 Feb

Apellis Pharmaceuticals Shares Reverse Course From Premarket Gains; Last Down 4.4%

THOMSON REUTERS
·
28 Feb

Apellis Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics

Zacks
·
28 Feb

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of Upcoming Economic Data

MT Newswires Live
·
28 Feb

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
28 Feb

BUZZ-Apellis rises after quarterly revenue beats estimates

Reuters
·
28 Feb

Apellis Pharmaceuticals Shares up 6.8% Premarket After Q4 Results

THOMSON REUTERS
·
28 Feb

Apellis Pharmaceuticals Q4 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
28 Feb

Apellis Pharmaceuticals' Cash And Cash Equivalents Of $411.3M As Of December 31, 2024; Projected Revenues And Cash Expected To Be Sufficient To Fund Operations To Profitability

Benzinga
·
28 Feb

Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 Net Loss $-0.29 a Share, vs. FactSet Est of $-0.37 Loss

MT Newswires Live
·
28 Feb

Stock Track | Apellis Pharmaceuticals Soars 9.62% Pre-Market on Revenue Growth Despite Q4 Loss

Stock Track
·
28 Feb

BRIEF-Apellis Pharmaceuticals Q4 Basic EPS USD -0.29

Reuters
·
28 Feb

Apellis Pharmaceuticals Q4 Product Revenue USD 191.172 Million

THOMSON REUTERS
·
28 Feb